Navigation Links
Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems.
Date:12/5/2008

Healthcare technology experts from Analog Devices, Inc. (ADI) took part in the MIT Next-Generation Medical Electronic Systems Forum held December 4-5, 2008, in Cambridge, Mass. Analog Devices Healthcare Segment Director Patrick O’Doherty spoke about healthcare market segmentation and trends affecting the design of next-generation medical equipment. ADI’s Healthcare Team Technology Director Tom O’Dwyer participated in a panel discussion on the opportunities and commercialization challenges facing developers of integrated circuits and systems. The two-day MIT forum was attended by experts from academia, the semiconductor and medical device industry, and the medical profession to exchange technical ideas, explore collaboration opportunities and define directions related to healthcare systems.

CAMBRIDGE, Mass. (Business Wire EON) December 5, 2008 -- "We are excited to have active participation and insights from ADI at the forum," said Professor Anantha Chandrakasan, director of MIT's Microsystems Technology Laboratories and chair of the Medical Electronics Workshop. "The development of next-generation implantable and wearable medical electronics will require an active collaboration between industry, medical professionals, and academia. ADI's presentations at the forum are critical in defining the opportunities and challenges for medical electronics."

During his talk, Patrick O'Doherty described how increasingly complex portable medical systems are moving from hospitals to points of primary care, such as doctors' offices, ambulances, and even into patients' homes. "As sophisticated healthcare technology increasingly migrates toward points of care and into the home, medical system requirements are becoming much more challenging in terms of required size, cost, robustness, performance, and ease of use," said O'Doherty. "Analog semiconductor ma
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TIs Portfolio of Embedded Processors and Analog Products
2. Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008.
3. Video: TI unveils industrys first family of complete analog front ends for superior ultrasound systems
4. Varian, Inc. Acquires Analogix Business
5. Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices
6. Dr. Blair Keagy Launches MPAnalytics, Inc. Medical Consultant Group : MPAnalytics, a Medical Consultant Group, Provides Market Analysis and Guidance for New Medical Devices, Technology, and Clinical Trial Protocol
7. MP3 Player Headphones May Throw Off Cardiac Devices
8. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
9. InHealth awards grants to study impact of medical diagnostics and devices on patients, health care
10. New Vascular Access Medical Devices Launched by Navilyst Medical
11. NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry :  ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 
(Date:9/2/2015)... , ... September 02, 2015 , ... Based in Beverly ... fleet of truly superb luxury vehicles based on which of the latest and greatest ... the latest step forward in pursuit of this goal: a 2015 Rolls Royce ...
(Date:9/2/2015)... DC (PRWEB) , ... September 02, 2015 , ... Telehealth ... American Well Corp., contracted to handle the telehealth services of more than 12 Blues ... Cross and Blue Shield Plans takes a look this growing trend, interviewing executives at ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... Fort Lauderdale, FL (PRWEB) , ... September 02, ... ... cost for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision ... with hospitalized Medicare patients – is likely to average approximately $71,000 or roughly ...
(Date:9/2/2015)... Bryn Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Location: Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, ... justCommunity, Inc., will host a day-long seminar featuring New York Times best-selling author Sam ...
Breaking Medicine News(10 mins):Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2
... women,s risk gets even smaller 10 years after stopping ... News) -- Women taking oral contraceptives are at a ... decade after stopping the pill even this very small ... that finding doesn,t change the recommendation for women to ...
... year over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. ... today announced its results for the quarter ended,September 30, 2007. Revenue ... of 16.3%, over the prior year quarter. The,primary drivers of the ...
... Highlighted by Continued Momentum in Global Commercialization, Program for Once-Daily ... ... III Study -, LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - ... the third quarter of fiscal,2007, ended September 30, 2007. All ...
... event in 2007, net loss stable ... otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - ... company, today announced financial results for the first,quarter of ... "We are also focused on the successful completion of ...
... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...
... Support Continued Advancement of Novel Technology and ... ... Inc., a,privately-held therapeutic antibody product company, today announced that,it has raised ... A/S.,Additional investors participating significantly in the round were Frazier,Healthcare Ventures and ...
Cached Medicine News:Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 14
(Date:9/2/2015)... Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... President and Chief Executive Officer, will present a ... Investment Conference, sponsored by H.C. Wainwright ... 8-10, 2015 at the St. Regis Hotel in ...
(Date:9/2/2015)... Sept. 2, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its affiliate has entered into a definitive agreement under ... , Inc. (NASDAQ: SURG ) for $6.50 per ... payment, Synergetics stockholders will receive additional cash payments of ... are achieved following the closing.  The transaction is expected ...
(Date:9/2/2015)... Tumultuous market conditions – including changes in ... activity – have led more than half of today,s ... reps. This marks the first time that the number ... point, according to the spring 2015 AccessMonitor™ report ... . AccessMonitor™ aggregates sales-call records ...
Breaking Medicine Technology:RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: